作者
Peter R Galle, Richard S Finn, Shukui Qin, Masafumi Ikeda, Andrew X Zhu, Tae-You Kim, Masatoshi Kudo, Valeriy Breder, Philippe Merle, Ahmed Kaseb, Daneng Li, Sohail Mulla, Wendy Verret, Derek-Zhen Xu, Sairy Hernandez, Beiying Ding, Juan Liu, Chen Huang, Ho Yeong Lim, Ann-Lii Cheng, Michel Ducreux
发表日期
2021/7/1
期刊
The Lancet Oncology
卷号
22
期号
7
页码范围
991-1001
出版商
Elsevier
简介
Background
Understanding patients' experience of cancer treatment is important. We aimed to evaluate patient-reported outcomes (PROs) with atezolizumab plus bevacizumab versus sorafenib in patients with advanced hepatocellular carcinoma in the IMbrave150 trial, which has already shown significant overall survival and progression-free survival benefits with this combination therapy.
Methods
We did an open-label, randomised, phase 3 trial in 111 hospitals and cancer centres across 17 countries or regions. We included patients aged 18 years or older with systemic, treatment-naive, histologically, cytologically, or clinically confirmed unresectable hepatocellular carcinoma and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, with disease that was not amenable to curative surgical or locoregional therapies, or progressive disease after surgical or locoregional therapies. Participants …
学术搜索中的文章
PR Galle, RS Finn, S Qin, M Ikeda, AX Zhu, TY Kim… - The Lancet Oncology, 2021